Trials / Completed
CompletedNCT00503204
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cediranib | oral tablet |
| DRUG | Lomustine | oral capsule |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-07-18
- Last updated
- 2009-11-25
Locations
2 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00503204. Inclusion in this directory is not an endorsement.